Corticosteroid (CS) use and risk of adverse events (AEs) in patients (pts) treated for metastatic hormone-sensitive prostate cancer (mHSPC).

Authors: Umang Swami, Samantha Shao, Tamuno Alfred, Maelys Touya, Lingtao Frank Cao, Pinal Kamdar, Jasmina I. Ivanova, Johanna Celli, David Nimke

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17097

Source: Full article

---

Abstract

e17097